据我们所知,这是卵巢早衰妇女口服促性腺激素释放激素(GnRH)拮抗剂治疗后健康婴儿妊娠的首例病例.一名36岁的女性在被以前的医生诊断为卵巢早衰后出现在我们医院。我们服用了克罗米芬,人类更年期促性腺激素(hMG),GnRH拮抗剂(注射)与雌激素替代治疗11个周期(27个月),但未观察到卵泡发育。当口服GnRH拮抗剂(relugolix),它最近变得可用,在第12周期中使用,在刺激的第14天证实了13毫米的卵泡生长。刺激后,继续使用hMG和GnRH拮抗剂(注射),和成熟触发器,人绒毛膜促性腺激素10000IU,被管理。成功取出卵母细胞,进行卵胞浆内单精子注射和冷冻胚胎移植,胎儿心跳得到证实。患者被送进围产期管理设施。她在41周+2时通过剖宫产分娩了一个3,732克的健康婴儿。该病例显示了使用口服GnRH拮抗剂作为不孕症治疗选择的可能性。
To the best of our knowledge, this is the first case of pregnancy with a healthy baby after treatment with an oral gonadotropin-releasing hormone (GnRH) antagonist in women with premature ovarian insufficiency. A 36-year-old female presented at our hospital after being diagnosed with premature ovarian insufficiency by a previous doctor. We administered clomiphene, human menopausal gonadotropin (hMG), and GnRH antagonist (injection) together with estrogen replacement for 11 cycles (27 months), but no follicular development was observed. When the oral GnRH antagonist (relugolix), which has recently become available, was used in the 12th cycle, follicular growth of 13 mm was confirmed on the 14th day of stimulation. After stimulation, the use of hMG and GnRH antagonist (injection) was continued, and a maturation trigger, human chorionic gonadotropin 10000 IU, was administered. Oocyte retrieval was performed successfully, intracytoplasmic sperm injection and frozen embryo transfer were performed, and fetal heartbeat was confirmed. The patient was admitted to the perinatal management facility. She delivered a healthy baby of 3,732 g via cesarean section at 41 weeks +2. This case shows the possibility of using an oral GnRH antagonist as an option for infertility treatment.